A promising development for OC patients...

[shyney]

Here’s a recent article that shows a promising development for ovarian cancer patients-- wanted to share!

A study on a PARP inhibitor, niraparib, showed that “Niraparib significantly improved progression-free survival in patients with platinum-sensitive recurrent ovarian cancer, regardless of BRCA mutation status.”

The median progression-free survival for patients given niraparib was 2 years, as opposed to 5.5 months.

PARP inhibitors work by targeting “HRD, a defect in DNA repair that, if unchecked, allows cancer to grow, proliferate, and acquire the biological immortality that characterizes fatal ovarian cancer.”

See the full article here: medpagetoday.com/meetingcov...

[SBlau Partner]

Hi Miyoshi, Thanks for sending your address. We will send you a book in the next few weeks. Feel free to delete this post, if you want since the post is public. Thanks!

[miyoshi in reply to SBlau]

Thank you!